🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Saurabh Dahiya

University of Maryland, Baltimore

ORCID: 0000-0001-8291-1796

Also affiliated with University of Maryland Medical Center, Palo Alto University, Stanford Blood Center, Stanford Medicine, Stanford University

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study”.

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

The Lancet(2024)10.1016/s0140-6736(24)00746-3
N/A
1.4DataRank · unranked
60 citations

John H. Baird, Anne Marijn Kramer, Hrishikesh K. Srinagesh, Shabnum Patel, Annie Kathleen Brown +43 more

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2020)10.1200/jco.19.02104
N/A
1.0DataRank · unranked
800 citations

Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin +23 more

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Blood(2025)10.1182/blood.2024026446
N/A
0.900DataRank · unranked
39 citations

Anna Pavlova, Alejandro Villar‐Prados, Cameron S. Bader, Bryan J. Xie, Lori Muffly +23 more

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2024)10.1200/jco.23.02786
N/A
0.650DataRank · unranked
75 citations

Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin +27 more

The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae209
N/A
0.584DataRank · unranked
15 citations

Kathleen Van Dyk, Sheri J. Hartman, Thuy T. Koll, Christina K. Cramer, Glenn J. Lesser +30 more

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy

Blood(2022)10.1182/blood.2022016175
N/A
0.529DataRank · unranked
33 citations

Tim Luetkens, Destiny Omili, Thierry Iraguha, Forat Lutfi, Nancy M. Hardy +19 more

Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series

Haematologica(2024)10.3324/haematol.2023.284784
N/A
0.434DataRank · unranked
17 citations

Michael J. Eckrich, Keagan G. Lipak, Bonnie Yates, Constance M. Yuan, Hao‐Wei Wang +6 more

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias

Research Square(2025)10.21203/rs.3.rs-7746241/v1
N/A
0.104DataRank · unranked
1 citations

Mark P. Hamilton, Nick Phillips, Troy Noordenbos, Jan Boegeholz, Takeshi Sugio +32 more

CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity

Blood Advances(2024)10.1182/bloodadvances.2024012637
N/A
0DataRank · unranked
24 citations

Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis, Nadia Kirmani +27 more

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Blood Advances(2023)10.1182/bloodadvances.2023011489
N/A
0DataRank · unranked
26 citations

Miriam T. Jacobs, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin +21 more

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

New England Journal of Medicine(2024)10.1056/nejmoa2401361
N/A
0DataRank · unranked
190 citations

Takeshi Sugio, Troy Noordenbos, Shuyu Shi, Philip L. Bulterys, Chih Long Liu +12 more

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2022009426
N/A
0DataRank · unranked
29 citations

Gregory J. Kimmel, Matthew J. Frank, Ali Bukhari, Nasheed Hossain, Michael D. Jain +5 more

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-008975
N/A
0DataRank · unranked
16 citations

Eric Lau, Mark Hamilton, Anmol Goyal, Hrishi Srinagesh, Alexandria Jensen +26 more